These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 17252020

  • 1. JAK3 mutations occur in acute megakaryoblastic leukemia both in Down syndrome children and non-Down syndrome adults.
    Kiyoi H, Yamaji S, Kojima S, Naoe T.
    Leukemia; 2007 Mar; 21(3):574-6. PubMed ID: 17252020
    [No Abstract] [Full Text] [Related]

  • 2. Acute megakaryoblastic leukemia without GATA1 mutation after transient myeloproliferative disorder in an infant without Down syndrome.
    Inaba H, Londero M, Maurer SH, Onciu M, Ge Y, Taub JW, Rubnitz JE, Raimondi SC.
    J Clin Oncol; 2011 Mar 20; 29(9):e230-3. PubMed ID: 21205752
    [No Abstract] [Full Text] [Related]

  • 3. Development of acute megakaryoblastic leukemia from a minor clone in a Down syndrome patient with clinically overt transient myeloproliferative disorder.
    Xu G, Kato K, Toki T, Takahashi Y, Terui K, Ito E.
    J Pediatr Hematol Oncol; 2006 Oct 20; 28(10):696-8. PubMed ID: 17023834
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Acute megakaryoblastic leukemia and severe pulmonary fibrosis in a child with Down syndrome: successful treatment with ultra low-dose cytarabine using GATA1 mutation to monitor minimal residual disease.
    Moritake H, Yamada A, Kimoto Y, Sawa D, Shimonodan H, Nunoi H.
    Am J Hematol; 2012 Apr 20; 87(4):447-50. PubMed ID: 22389016
    [No Abstract] [Full Text] [Related]

  • 7. Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome.
    Greene ME, Mundschau G, Wechsler J, McDevitt M, Gamis A, Karp J, Gurbuxani S, Arceci R, Crispino JD.
    Blood Cells Mol Dis; 2003 Apr 20; 31(3):351-6. PubMed ID: 14636651
    [Abstract] [Full Text] [Related]

  • 8. GATA1 mutations in Down syndrome: implications for biology and diagnosis of children with transient myeloproliferative disorder and acute megakaryoblastic leukemia.
    Crispino JD.
    Pediatr Blood Cancer; 2005 Jan 20; 44(1):40-4. PubMed ID: 15390312
    [Abstract] [Full Text] [Related]

  • 9. GATA1 mutations in myeloproliferative disorders: nomenclature standardization and review of the literature.
    Splendore A, Magalhães IQ, Pombo-de-Oliveira MS.
    Hum Mutat; 2005 Oct 20; 26(4):390-2. PubMed ID: 16134163
    [No Abstract] [Full Text] [Related]

  • 10. GATA 1 mutations as clonal markers of minimal residual disease in acute megakaryoblastic leukemia of Down syndrome--a new tool with significant potential applications.
    Hitzler J, Zipursky A.
    Leuk Res; 2005 Nov 20; 29(11):1239-40. PubMed ID: 15925405
    [No Abstract] [Full Text] [Related]

  • 11. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome.
    Wechsler J, Greene M, McDevitt MA, Anastasi J, Karp JE, Le Beau MM, Crispino JD.
    Nat Genet; 2002 Sep 20; 32(1):148-52. PubMed ID: 12172547
    [Abstract] [Full Text] [Related]

  • 12. Risk for leukemia in infants without Down syndrome who have transient myeloproliferative disorder.
    Cushing T, Clericuzio CL, Wilson CS, Taub JW, Ge Y, Reichard KK, Winter SS.
    J Pediatr; 2006 May 20; 148(5):687-9. PubMed ID: 16737888
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Molecular insights into Down syndrome-associated leukemia.
    Vyas P, Crispino JD.
    Curr Opin Pediatr; 2007 Feb 20; 19(1):9-14. PubMed ID: 17224656
    [Abstract] [Full Text] [Related]

  • 15. GATA1 as a new target to detect minimal residual disease in both transient leukemia and megakaryoblastic leukemia of Down syndrome.
    Pine SR, Guo Q, Yin C, Jayabose S, Levendoglu-Tugal O, Ozkaynak MF, Sandoval C.
    Leuk Res; 2005 Nov 20; 29(11):1353-6. PubMed ID: 15916804
    [Abstract] [Full Text] [Related]

  • 16. Loss-of-function JAK3 mutations in TMD and AMKL of Down syndrome.
    De Vita S, Mulligan C, McElwaine S, Dagna-Bricarelli F, Spinelli M, Basso G, Nizetic D, Groet J.
    Br J Haematol; 2007 May 20; 137(4):337-41. PubMed ID: 17456055
    [Abstract] [Full Text] [Related]

  • 17. Exome sequencing identifies putative drivers of progression of transient myeloproliferative disorder to AMKL in infants with Down syndrome.
    Nikolaev SI, Santoni F, Vannier A, Falconnet E, Giarin E, Basso G, Hoischen A, Veltman JA, Groet J, Nizetic D, Antonarakis SE.
    Blood; 2013 Jul 25; 122(4):554-61. PubMed ID: 23733339
    [Abstract] [Full Text] [Related]

  • 18. Highly sensitive detection of GATA1 mutations in patients with myeloid leukemia associated with Down syndrome by combining Sanger and targeted next generation sequencing.
    Terui K, Toki T, Taga T, Iwamoto S, Miyamura T, Hasegawa D, Moritake H, Hama A, Nakashima K, Kanezaki R, Kudo K, Saito AM, Horibe K, Adachi S, Tomizawa D, Ito E.
    Genes Chromosomes Cancer; 2020 Mar 25; 59(3):160-167. PubMed ID: 31606922
    [Abstract] [Full Text] [Related]

  • 19. Acute megakaryoblastic leukaemia (AMKL) and transient myeloproliferative disorder (TMD) in Down syndrome: a multi-step model of myeloid leukaemogenesis.
    Roy A, Roberts I, Norton A, Vyas P.
    Br J Haematol; 2009 Oct 25; 147(1):3-12. PubMed ID: 19594743
    [Abstract] [Full Text] [Related]

  • 20. Molecular lesions in childhood and adult acute megakaryoblastic leukaemia.
    Hama A, Muramatsu H, Makishima H, Sugimoto Y, Szpurka H, Jasek M, O'Keefe C, Takahashi Y, Sakaguchi H, Doisaki S, Shimada A, Watanabe N, Kato K, Kiyoi H, Naoe T, Kojima S, Maciejewski JP.
    Br J Haematol; 2012 Feb 25; 156(3):316-25. PubMed ID: 22122069
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.